January 25, 2024

Clairvo Technologies Co., Ltd. (Headquarters: Chiyoda, Tokyo; CEO: Riichi Yamada, hereafter "Clairvo") has entered into an exclusive business alliance agreement with Zhejiang Yizhun Medical AI Technology Co.,Ltd. (Headquarters: Zhejiang, People's Republic of China; CEO: Chenchong Lv, hereafter “Yizhun”).

With the conclusion of the agreement, Yizhun and Clairvo aim to obtain necessary regulatory approvals to market a product in Japan.
The medical device programs developed by Yizhun assists in the detection of mammary tumors from mammary X-ray images.
In China, the product havs already obtained NMPA3.

In Japan, breast cancer is the leading cancer among all cancers by body part among women. It is estimated that one in nine women is affected.
On the other hand, if breast cancer is detected and treated early in Stage I, the five-year survival rate is more than 90% ^[1]. Therefore, early detection is considered crucial.

Based on the company's philosophy of "Innovation For Healthcare", Clairvo, together with Yizhun, aims to support the early detection of breast tumors, contribute to the improvement of women's health, and help people’s healthy lives.

 
【About Yizhun】

Since 2014, Yizhun has been committed to research and innovation in artificial intelligence technologies related to medical imaging, with a particular focus on breast cancer screening and treatment.

As a solution provider for breast cancer screening, Yizhun is committed to product development from a variety of screening and treatment perspectives and conveying the importance of early screening, early diagnosis, and early treatment of breast tumors. For more information, visit https://www.yizhun-ai.com/ .

*1 : Reference